肠道菌群
梭状芽孢杆菌
厚壁菌
丁酸盐
二甲双胍
医学
糖尿病
2型糖尿病
2型糖尿病
内科学
内分泌学
生理学
免疫学
食品科学
生物
细菌
发酵
遗传学
16S核糖体RNA
作者
Fatin Umirah,Chin Fen Neoh,Kalavathy Ramasamy,Siong Meng Lim
标识
DOI:10.1016/j.diabres.2021.108689
摘要
Aims This systematic review summarised the latest findings on differential composition of gut microbiota in T2DM. Methods Literature search was performed using electronic databases. Relevant studies were identified, extracted and assessed for risk of bias. The primary outcome of this systematic review was the composition of gut microbiota in healthy controls and T2DM while the secondary outcomes included the correlation of gut microbiota with metabolic parameters. Results Thirteen case-control studies involving 575 T2DM and 840 healthy controls were included. T2DM patients exhibited a marked increase in lactobacilli. Six studies found lactobacilli to predominate the gut of T2DM patients; however, this could be confounded by the types of antihyperglyacemic medications. Conversely, butyrate producers dominate the gut of healthy controls. In T2DM patients, butyrate producers were surprisingly higher in those taking metformin intake than those not taking the drug. Whilst lactobacilli were found to be higher with increased plasma glucose, conflicting correlations were observed between various genera and anthropometric measurements, dietary intake, lipid profiles and inflammatory markers. There were moderate to strong significant positive correlations between the class Clostridia and phylum Firmicutes with pro-inflammatory IFN-γ as well as between Negativicutes and IL-6. Conclusions Altogether, butyrate-producing bacteria are negatively correlated to glycaemic parameters. Lactobacilli are higher in T2DM patients and Firmicutes is correlated with inflammation.
科研通智能强力驱动
Strongly Powered by AbleSci AI